At JRG Partners, this is the kind of search we run every day, so this piece reflects practice rather than theory. The VP of Clinical Affairs sits at the intersection of science, regulation, and commercial strategy, designing and running the clinical evidence that determines whether a device can be approved, reimbursed, and sold. The traits that distinguish a strong clinical affairs leader are specific: scientific rigor, regulatory awareness, and the judgment to design studies that serve both approval and commercial goals.
Key Takeaways
- Clinical affairs generates the evidence that drives approval and reimbursement.
- Look for scientific rigor combined with regulatory and commercial awareness.
- Study design judgment is the highest-leverage trait.
- Strong relationships with clinical investigators and sites matter.
- The role bridges science, regulation, and commercial strategy.
Scientific Rigor With Strategic Awareness
The foundation of a strong VP of Clinical Affairs is scientific and clinical rigor: the ability to design sound studies, interpret data honestly, and maintain the scientific integrity that regulators and clinicians demand. But rigor alone is not enough. The best clinical affairs leaders pair it with strategic awareness, understanding how clinical evidence supports the regulatory pathway, the reimbursement case, and the commercial claims the company wants to make. A leader who is scientifically excellent but strategically naive may run studies that satisfy science without serving the business; one who is strategically savvy but scientifically loose creates regulatory risk. The combination is what matters.
Study Design Judgment
The highest-leverage decisions a clinical affairs leader makes are in study design: what endpoints to use, what population to study, how large and how long a trial must be, and what evidence will actually satisfy the FDA and payors. These choices determine cost, timeline, and whether the resulting evidence supports approval and reimbursement. A leader with strong study design judgment can save a company years and enormous cost by designing the right study the first time, while poor design can produce evidence that fails to support the claims the company needs. In assessment, probe the candidate’s actual study design decisions and what resulted from them.
Investigator and Site Relationships
Clinical studies run through investigators, sites, and clinical stakeholders, and a clinical affairs leader’s ability to build and manage those relationships materially affects enrollment, data quality, and timelines. A leader with strong credibility among clinical investigators can recruit better sites, enroll faster, and generate higher-quality data, while one without those relationships struggles with the operational realities of running trials. This relational and operational dimension is often underweighted in hiring, but it is frequently the difference between a study that runs on time and one that stalls, so assess the candidate’s track record with investigators and sites.
What This Looks Like in Practice
A device company hiring a VP of Clinical Affairs assesses scientific rigor, strategic awareness of how evidence serves regulatory and commercial goals, demonstrated study design judgment, and credibility with clinical investigators and sites. It probes actual design decisions and their outcomes. It does not hire on scientific credentials alone without strategic awareness, or overlook the operational and relational dimension that determines whether studies actually run well.
The Mistake Employers Keep Making
The most common mistake is hiring purely on scientific or academic credentials, assuming that strong science translates into strong clinical affairs leadership. It often does not: a scientifically excellent leader who lacks regulatory awareness may design studies that do not support the approval pathway, and one without operational and investigator relationships may run trials that stall. The company mistakes scientific pedigree for the blend of rigor, strategy, and operational credibility the role actually requires.
Traits That Distinguish a Strong Clinical Affairs Leader
| Trait | Why It Matters |
|---|---|
| Scientific and clinical rigor | Credibility with regulators and clinicians |
| Regulatory awareness | Evidence must support the pathway |
| Commercial awareness | Evidence must support claims and reimbursement |
| Study design judgment | Determines cost, timeline, and success |
| Investigator relationships | Drives enrollment and data quality |
The Bottom Line
A successful VP of Clinical Affairs combines scientific rigor with regulatory and commercial awareness, exercises strong study design judgment, and brings credibility with investigators and sites, so hire for that combination rather than scientific credentials alone, since clinical evidence determines whether a device can be approved, reimbursed, and sold. Matching the person to the real demands of the role, not just a strong generalist to a title, is what separates success from expensive disappointment.
Related Reading
For more, see Top Qualities to Look for in a VP of Regulatory Affairs (MedTech), Hiring a VP of R&D for Diagnostics Companies, How to Hire a Medical Device CEO Who Understands FDA Pathways.
Frequently Asked Questions
- Q: What does a VP of Clinical Affairs do?
- A: They design and run the clinical evidence programs that determine whether a device can be approved, reimbursed, and sold, bridging science, regulation, and commercial strategy.
- Q: What is the most important trait?
- A: Study design judgment, since decisions about endpoints, population, size, and duration determine cost, timeline, and whether the evidence supports approval and reimbursement.
- Q: Why does regulatory awareness matter for clinical affairs?
- A: Because clinical evidence must support the regulatory pathway, so a leader who designs scientifically sound studies that do not serve the approval strategy creates costly problems.
- Q: Do investigator relationships matter?
- A: Yes; credibility with clinical investigators and sites affects enrollment, data quality, and timelines, and is often the difference between a study that runs on time and one that stalls.
- Q: What is the common hiring mistake?
- A: Hiring on scientific or academic credentials alone, without the regulatory awareness, commercial understanding, and operational credibility the role requires.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
